留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

放射性核素诊疗现状与未来展望

罗亚平 李方

罗亚平, 李方. 放射性核素诊疗现状与未来展望[J]. 协和医学杂志, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236
引用本文: 罗亚平, 李方. 放射性核素诊疗现状与未来展望[J]. 协和医学杂志, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236
LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236
Citation: LUO Yaping, LI Fang. Current Status and Future Prospects of Theranostics with Radiopharmaceuticals[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 669-672. doi: 10.12290/xhyxzz.2023-0236

放射性核素诊疗现状与未来展望

doi: 10.12290/xhyxzz.2023-0236
详细信息
    通讯作者:

    李方, E-mail: lifang@pumch.cn

  • 中图分类号: R445.5;R-1

Current Status and Future Prospects of Theranostics with Radiopharmaceuticals

More Information
  • 摘要: 放射性核素诊疗(即核医学技术)是利用放射性核素进行疾病诊断和治疗的技术,其已历经百余年发展历程。得益于设备和放射性药物的进步、临床需求的增加、国家政策的支持以及全球化合作的开启,核医学技术得以快速发展。时至今日,核医学技术已成为一种广泛应用于影像诊断及治疗的技术,在临床中发挥重要且独特的价值。未来,核医学仍将在影像诊断、放射性核素治疗、人工智能领域继续蓬勃发展,并将取得更大的进步。
    作者贡献:罗亚平负责文献查阅、论文撰写及修订;李方负责选题设计及论文指导。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Carlsson S. A glance at the history of nuclear medicine[J]. Acta Oncol, 1995, 34: 1095-1102. doi:  10.3109/02841869509127236
    [2] Middlebrooks JT. A Half-Century of Nuclear Medicine[J]. J Nucl Med Technol, 2020, 48: 40S-42S. doi:  10.2967/jnmt.119.233486
    [3] Hutton BF. The origins of SPECT and SPECT/CT[J]. Eur J Nucl Med Mol Imaging, 2014, 41: S3-S16. doi:  10.1007/s00259-013-2606-5
    [4] Verburg FA, Heinzel A, Hänscheid H, et al. Nothing new under the nuclear sun: towards 80 years of theranostics in nuclear medicine[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 199-201. doi:  10.1007/s00259-013-2609-2
    [5] Zimmerman RE. Gamma cameras-state of the art[J]. Med Instrum, 1979, 13: 161-164.
    [6] Wagner HN Jr. A brief history of positron emission tomography (PET)[J]. Semin Nucl Med, 1998, 28: 213-220. doi:  10.1016/S0001-2998(98)80027-5
    [7] Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors[J]. N Engl J Med, 2017, 376: 125-135. doi:  10.1056/NEJMoa1607427
    [8] Fallah J, Agrawal S, Gittleman H, et al. FDA Approval Summary: Lutetium Lu(177) Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer[J]. Clin Cancer Res, 2023, 29: 1651-1657. doi:  10.1158/1078-0432.CCR-22-2875
    [9] Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium[J]. Thyroid, 2019, 29: 7-26. doi:  10.1089/thy.2017.0129
    [10] Singh S, Hope TA, Bergsland EB, et al. Consensus Report of the 2021 National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting[J]. J Natl Cancer Inst, 2023. doi:  10.1093/jnci/djad096.
    [11] Ferretti S, Mercinelli C, Marandino L, et al. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs[J]. Res Rep Urol, 2023, 15: 243-259.
    [12] Otte A, van de Wiele C, Dierckx RA. Radiolabeled immunotherapy in non-Hodgkin's lymphoma treatment: the next step[J]. Nucl Med Commun, 2009, 30: 5-15. doi:  10.1097/MNM.0b013e328313e565
    [13] Voutsinas N, Lekperic S, Barazani S, et al. Treatment of Primary Liver Tumors and Liver Metastases, Part 1: Nuclear Medicine Techniques[J]. J Nucl Med, 2018, 59: 1649-1654. doi:  10.2967/jnumed.116.186346
    [14] Velikyan I. Prospective of (68)Ga-radiopharmaceutical development[J]. Theranostics, 2013, 4: 47-80.
    [15] Velikyan I. Continued rapid growth in (68) Ga applications: update 2013 to June 2014[J]. J Labelled Comp Radiopharm, 2015, 58: 99-121. doi:  10.1002/jlcr.3250
    [16] Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med, 2021, 385: 1091-1103. doi:  10.1056/NEJMoa2107322
    [17] Cheng X, Li F, Liang L. Boron Neutron Capture Therapy: Clinical Application and Research Progress[J]. Curr Oncol, 2022, 29: 7868-7886. doi:  10.3390/curroncol29100622
    [18] Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT[J]. Pharmaceuticals (Basel), 2021, 14: 1005. doi:  10.3390/ph14101005
    [19] Nensa F, Demircioglu A, Rischpler C. Artificial Intelligence in Nuclear Medicine[J]. J Nucl Med, 2019, 60: 29S-37S. doi:  10.2967/jnumed.118.220590
    [20] Seifert R, Weber M, Kocakavuk E, et al. Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives[J]. Semin Nucl Med, 2021, 51: 170-177. doi:  10.1053/j.semnuclmed.2020.08.003
  • 加载中
计量
  • 文章访问数:  1999
  • HTML全文浏览量:  96
  • PDF下载量:  443
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-14
  • 录用日期:  2023-07-18
  • 网络出版日期:  2023-07-20
  • 刊出日期:  2023-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!